Actuate Therapeutics to Present Preclinical Elraglusib Data at ENA 2026
Actuate Therapeutics says it will present preclinical data on the antitumor and immune activation activity of its elraglusib oral tablet in advanced melanoma models at ENA 2026.
Actuate Therapeutics says it will present preclinical data on the antitumor and immune activation activity of its elraglusib oral tablet in advanced melanoma models at ENA 2026.